Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors
Authors:
- 28 August 2008
- journal article
- review article
- Published by Wiley in Haemophilia
- Vol. 14 (5) , 898-902
Abstract
Summary. Recombinant factor VIIa (rFVIIa, NovoSeven®) has been licensed for treatment of haemophilia with inhibitors in Europe since 1996 and in North America since 1999. Overall, approximately 1.5 million doses have since been administered. Safety data from licensure to April 2003 revealed 25 thromboembolic (TE) adverse events (AE) from over 700 000 doses given, a remarkably low incidence of TE events. Recent reports have cited a higher prevalence of TE events with rFVIIa use, especially when used off‐label. This report reviews the TE and fatal events with use of rFVIIa for congenital and acquired haemophilia A or B from May 2003 to December 2006. Approximately 800 000 standard doses of rFVIIa have been administered during this time frame. All clinical trials, spontaneous and solicited reports, as well as a detailed literature review, were included in the data analysis. There were a total of 30 TE events and 6 TE‐associated fatal events. Spontaneous reports captured 14/71 (20%) TE/AE and 2/34 TE‐associated/total fatal events. From solicited reports, 5/40 (12.5%) were associated with a TE and 1/32 TE‐associated fatal events. Literature review revealed 11/19 (58%) TE events and 3/6 TE‐associated fatal events. Despite the use of high‐dose rFVIIa (270 μg kg−1) in some clinical trials and registries, rFVIIa appears safe, when used for congenital and acquired haemophilia. The prevalence of TE associated with rFVIIa use is less than 4/100 000 and a TE‐associated fatal event is also extremely rare. However, use of rFVIIa for off‐label indications should continue to be monitored closely via clinical trials and carefully designed registries.Keywords
This publication has 15 references indexed in Scilit:
- Single 270 μg kg−1‐dose rFVIIa vs. standard 90 μg kg−1‐dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparisonHaemophilia, 2007
- Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgeryThrombosis and Haemostasis, 2007
- MedWatch: an important instrument for postlicensing surveillanceJournal of Thrombosis and Haemostasis, 2006
- A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitorsJournal of Thrombosis and Haemostasis, 2006
- Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitorsThrombosis and Haemostasis, 2006
- Comparative thrombotic event incidence after infusion of recombinant factor VIIa vs. factor VIII inhibitor bypass activity—reply to a rebuttalJournal of Thrombosis and Haemostasis, 2005
- Comparative thrombotic event incidence after infusion of recombinant factor VIIa vs. factor VIII inhibitor bypass activity—a rebuttalJournal of Thrombosis and Haemostasis, 2005
- Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society RegistryHaemophilia, 2005
- Thrombosis and recombinant factor VIIaJournal of Thrombosis and Haemostasis, 2004
- Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activityJournal of Thrombosis and Haemostasis, 2004